NO20052472L - 1-acyl-pyrrolidinderivater for behandling av virale infeksjoner. - Google Patents

1-acyl-pyrrolidinderivater for behandling av virale infeksjoner.

Info

Publication number
NO20052472L
NO20052472L NO20052472A NO20052472A NO20052472L NO 20052472 L NO20052472 L NO 20052472L NO 20052472 A NO20052472 A NO 20052472A NO 20052472 A NO20052472 A NO 20052472A NO 20052472 L NO20052472 L NO 20052472L
Authority
NO
Norway
Prior art keywords
alkyl
treatment
acyl
aryl
viral infections
Prior art date
Application number
NO20052472A
Other languages
English (en)
Norwegian (no)
Inventor
Pritom Shah
Charles David Hartley
Peter Howes
Dav Haigh
Deborah Lynette Jackson
Martin John Slater
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0224774A external-priority patent/GB0224774D0/en
Priority claimed from GB0229470A external-priority patent/GB0229470D0/en
Priority claimed from GB0317141A external-priority patent/GB0317141D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20052472L publication Critical patent/NO20052472L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
NO20052472A 2002-10-24 2005-05-23 1-acyl-pyrrolidinderivater for behandling av virale infeksjoner. NO20052472L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0224774A GB0224774D0 (en) 2002-10-24 2002-10-24 Compounds
GB0229470A GB0229470D0 (en) 2002-12-18 2002-12-18 Compounds
GB0317141A GB0317141D0 (en) 2003-07-22 2003-07-22 Compounds
PCT/EP2003/011813 WO2004037818A1 (en) 2002-10-24 2003-10-22 1-acyl-pyrrolidine derivatives for the treatment of viral infections

Publications (1)

Publication Number Publication Date
NO20052472L true NO20052472L (no) 2005-05-23

Family

ID=32180212

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052472A NO20052472L (no) 2002-10-24 2005-05-23 1-acyl-pyrrolidinderivater for behandling av virale infeksjoner.

Country Status (18)

Country Link
US (1) US7304087B2 (de)
EP (1) EP1554274B1 (de)
JP (1) JP2006506455A (de)
KR (1) KR20050057670A (de)
AR (1) AR041816A1 (de)
AT (1) ATE418554T1 (de)
AU (1) AU2003276172A1 (de)
BR (1) BR0315417A (de)
CA (1) CA2503471A1 (de)
CO (1) CO5550450A2 (de)
DE (1) DE60325498D1 (de)
IS (1) IS7851A (de)
MA (1) MA27524A1 (de)
MX (1) MXPA05004435A (de)
NO (1) NO20052472L (de)
PL (1) PL376454A1 (de)
TW (1) TW200418848A (de)
WO (1) WO2004037818A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0304494D0 (en) * 2003-02-27 2003-04-02 Glaxo Group Ltd Compounds
GB0408995D0 (en) * 2004-04-22 2004-05-26 Glaxo Group Ltd Compounds
GB0423673D0 (en) * 2004-10-25 2004-11-24 Glaxo Group Ltd Compounds
GB0423672D0 (en) * 2004-10-25 2004-11-24 Glaxo Group Ltd Compounds
WO2006050035A1 (en) 2004-10-29 2006-05-11 Schering Corporation Substituted 5-oxo pyrazoles and [1,2,4]triazoles as antiviral agents
GB0519488D0 (en) * 2005-09-23 2005-11-02 Glaxo Group Ltd Compounds
GB0519478D0 (en) * 2005-09-23 2005-11-02 Glaxo Group Ltd Compounds
GB0519485D0 (en) * 2005-09-23 2005-11-02 Glaxo Group Ltd Compounds
GB0519486D0 (en) * 2005-09-23 2005-11-02 Glaxo Group Ltd Compounds
JP2010520200A (ja) 2007-02-28 2010-06-10 クオナトウス ファーマシューティカルズ,インコーポレイテッド 特定のマトリックスメタロプロテイナーゼ(mmp)阻害剤を使用する肝疾患を治療する方法
EP2142215B1 (de) 2007-05-04 2012-03-07 Vertex Pharmceuticals Incorporated Kombinationstherapie zur behandlung von hiv-infektionen
US20090053175A1 (en) * 2007-08-24 2009-02-26 Yat Sun Or Substitute pyrrolidine derivatives
CN104710365A (zh) 2008-04-28 2015-06-17 旭化成制药株式会社 苯丙酸衍生物及其用途
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
BRPI0917013A2 (pt) 2008-08-11 2016-02-16 Glaxosmithkline Llc métodos para tratar doenças alérgicas e outras condições inflamatórias, e para tratar ou prevenir doença, composto, composição farmacêutica, e, uso de um composto
BRPI0917458A2 (pt) 2008-08-11 2015-12-01 Glaxosmithkline Llc composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto
WO2011098451A1 (en) 2010-02-10 2011-08-18 Glaxosmithkline Llc Purine derivatives and their pharmaceutical uses
DK2534149T3 (da) 2010-02-10 2015-01-05 Glaxosmithkline Llc 6-amino-2-{ [ (1s)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8h-purin-8-on-maleat
US9340530B2 (en) 2012-03-06 2016-05-17 Merck Sharp & Dohme Corp. Preparation and use of bicyclic himbacine derivatives as PAR-1 receptor antagonists
KR20160124157A (ko) 2014-02-20 2016-10-26 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 인간 인터페론의 유도인자로서의 피롤로[3,2]피리미딘 유도체
MX2017006302A (es) 2014-11-13 2018-02-16 Glaxosmithkline Biologicals Sa Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias.
CN107849084B (zh) 2015-12-03 2021-09-14 葛兰素史密斯克莱知识产权发展有限公司 作为sting调节剂的环状嘌呤二核苷酸
JP2019510802A (ja) 2016-04-07 2019-04-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited タンパク質調節物質として有用な複素環アミド
PT3440076T (pt) 2016-04-07 2022-07-29 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas úteis como modeladores de proteína
AU2018344902B2 (en) 2017-10-05 2021-06-03 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (STING) useful in treating HIV
CA3077337A1 (en) 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting)
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
US20220227761A1 (en) 2019-05-16 2022-07-21 Stingthera, Inc. Oxoacridinyl acetic acid derivatives and methods of use
WO2020232378A1 (en) 2019-05-16 2020-11-19 Silicon Swat, Inc. Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
EP4077318B1 (de) 2019-12-18 2025-10-15 Ctxt Pty Ltd Benzimidazol-dimere als modulatoren von sting

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977075A (en) 1995-04-21 1999-11-02 Novartis Ag N-aroylamino acid amides as endothelin inhibitors
AU1804299A (en) 1997-12-08 1999-06-28 Glycomed Incorporated Sialyl lewis x and sialyl lewis a glycomimetics
DE69938493T2 (de) 1998-01-26 2009-05-20 Massachusetts Institute Of Technology, Cambridge Endoskop zur erfassung von fluoreszenzbilder
CN1328546A (zh) 1998-04-23 2001-12-26 艾博特公司 作为神经氨酸酶抑制剂的吡咯烷
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
EP1118287B1 (de) * 2000-01-21 2004-11-24 Alois Ing. Sampl Steckbares Regalsystem
US6713502B2 (en) * 2000-05-05 2004-03-30 Smithkline Beecham Corporation Anti-infectives
EP1339708A2 (de) 2000-11-20 2003-09-03 Scios Inc. Indol-enthaltende inhibitoren von p38 kinase
JP2005511574A (ja) 2001-10-26 2005-04-28 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー Nachrアゴニストとしてのn−アザビシクロ−置換ヘテロ二環式カルボキサミド
WO2003037893A1 (en) 2001-11-02 2003-05-08 Glaxo Group Limited Acyl dihydro pyrrole derivatives as hcv inhibitors
AU2002335950A1 (en) 2002-10-28 2004-05-13 Marquage Antivol Sherlock, Inc. Method of preventing theft of vehicles using intensive marking

Also Published As

Publication number Publication date
US20060258720A1 (en) 2006-11-16
AR041816A1 (es) 2005-06-01
ATE418554T1 (de) 2009-01-15
DE60325498D1 (de) 2009-02-05
JP2006506455A (ja) 2006-02-23
EP1554274B1 (de) 2008-12-24
MXPA05004435A (es) 2005-07-26
CO5550450A2 (es) 2005-08-31
US7304087B2 (en) 2007-12-04
KR20050057670A (ko) 2005-06-16
PL376454A1 (en) 2005-12-27
BR0315417A (pt) 2005-08-16
AU2003276172A1 (en) 2004-05-13
EP1554274A1 (de) 2005-07-20
WO2004037818A1 (en) 2004-05-06
TW200418848A (en) 2004-10-01
CA2503471A1 (en) 2004-05-06
IS7851A (is) 2005-05-19
MA27524A1 (fr) 2005-09-01

Similar Documents

Publication Publication Date Title
NO20052472L (no) 1-acyl-pyrrolidinderivater for behandling av virale infeksjoner.
NO20072547L (no) 4-metoksymetyl-pyrrolidin-2-karboksylsyreforbindelser og derivater derav som hepatitt C virusinhibitorer
TW200616994A (en) Novel thiophene derivatives
NO20061170L (no) Piperazinderivater for behandling av HIV-infeksjoner
NO20082934L (no) Antivirale nukleotider
AP1753A (en) Thiophene derivatives as antiviral agents for flavvivirus infection
NO20051527D0 (no) 3-(sulfonamidoetyl) -indol-derivater for anvendelse som glukocorticoid-mimetica ved behandling av inflammatoriske, allergiske og proliferative sykdommer.
NO20085269L (no) 2-tioksantinderivater som fungerer som MPO-inhibitorer
EA201101492A1 (ru) Аналоги тиофена для лечения или предупреждения флавивирусных инфекций
CA2443449A1 (en) Pyrazole derivatives for treating hiv
NO20076006L (no) Acetylenderivater
WO2006046030A3 (en) Tetracyclic indole derivatives as antiviral agents
NO20051165L (no) Benzotiazolderivater som har -adrenoerseptorantagonist aktivitet
WO2003084938A3 (en) Pyrimidone derivatives useful for the treatment of inflammatin and immunological diseases
NO20062370L (no) Amidderivater
NO20052580L (no) Blandinger for behandling av infeksjon av Flavivirida viruser
WO2002018324A3 (en) Immunoregulatory compounds, derivatives thereof and their use
WO2006027628A3 (en) Naphthalimide derivatives as antiviral agents
WO2008107502A8 (es) Composicion para el tratamiento de enfermedades infecciosas
NO20075409L (no) Substituerte aminoalkyl- og amidoalkyl-benzopyranderivater
NO20053133L (no) Kjemiske forbindelser.
NO20062491L (no) Benzoksazinderivter og deres anvendelse
MXPA06001039A (es) Derivados de nicotinamida utiles como inhibidores de pde4.
DE60318874D1 (en) Pyrazolderivate
NO983444D0 (no) Benzo(c)kinolizin derivater, deres fremstilling og anvendelse som 5<alfa>-reduktaseinhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application